방사성요오드 불응성 분화갑상선암의 치료, 현재의상황과 향후 전망

키워드

참고문헌 (87)

1. 김태용, "Current Status and Future Perspectives in Differentiated Thyroid Cancer", Endocrinology and Metabolism, 29(3), pp.217~225 (2014), 대한내분비학회
2. 정준기, "Radioiodine Therapy in Differentiated Thyroid Cancer: The First Targeted Therapy in Oncology", Endocrinology and Metabolism, 29(3), pp.233~239 (2014), 대한내분비학회
3. Durante C, "Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma : benefits and limits of radioiodine therapy", J Clin Endocrinol Metab, 91(8), pp.2892~2899 (2006)
4. Kim WG, "Redifferentiation therapy with 13-cis retinoic acids in radioiodine-resistant thyroid cancer", Endocr J, 56(1), pp.105~112 (2009)
5. Kebebew E, "Results of rosiglitazone therapy in patients with thyroglobulin-positive and radioiodine-negative advanced differentiated thyroid cancer", Thyroid, 19(9), pp.953~956 (2009)
6. Ho AL, "Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer", N Engl J Med, 368(7), pp.623~632 (2013)
7. Rothenberg SM, "Redifferentiation of iodine-refractory BRAF V600Emutant metastatic papillary thyroid cancer with dabrafenib", Clin Cancer Res, 21(5), pp.1028~1035 (2015)
8. Dunn LA, "Vemurafenib redifferentiation of BRAF mutant, RAI-refractory thyroid cancers", J Clin Endocrinol Metab, 104(5), pp.1417~1428 (2019)
9. Cancer Genome Atlas Research Network, "Integrated genomic characterization of papillary thyroid carcinoma", Cell, 159(3), pp.676~690 (2014)
10. Yen I, "ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma", Nature, 594(7863), pp.418~423 (2021)
11. Dadu R, "Efficacy and tolerability of vemurafenib in patients with BRAF(V600E)-positive papillary thyroid cancer:M.D. Anderson Cancer Center off label experience", J Clin Endocrinol Metab, 100(1), pp.E77~E81 (2015)
12. Consoli F, "Network indirect comparison of 3 BRAF +MEK inhibitors for the treatment of advanced BRAF mutated melanoma", Clin Transl Oncol, 22(6), pp.900~907 (2020)
13. Falchook GS, "BRAF inhibitor dabrafenib in patients with metastatic BRAF-mutant thyroid cancer", Thyroid, 25(1), pp.71~77 (2015)
14. Carr LL, "Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation", Clin Cancer Res, 16(21), pp.5260~5268 (2010)
15. Dadu R, "Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib", J Clin Endocrinol Metab, 99(6), pp.2086~2094 (2014)
16. Diez JJ, "Activity and safety of sunitinib in patients with advanced radioactive iodinerefractory differentiated thyroid carcinoma in clinical practice", Endocrine, 48(2), pp.582~588 (2015)
17. Leboulleux S, "Vandetanib in locally advanced or metastatic differentiated thyroid cancer : a randomised, double-blind, phase 2 trial", Lancet Oncol, 13(9), pp.897~905 (2012)
18. "Evaluation of efficacy, safety of vandetanib in patients with differentiated thyroid cancer (VERIIFY)"[URL]
19. Elisei R, "Cabozantinib in progressive medullary thyroid cancer", J Clin Oncol, 31(29), pp.3639~3646 (2013)
20. "A study of two different doses of cabozantinib (XL184) in progressive, metastatic medullary thyroid cancer (EXAMINER)"[URL]
21. Cabanillas ME, "A phase I study of cabozantinib(XL184)in patients with differentiated thyroid cancer", Thyroid, 24(10), pp.1508~1514 (2014)
22. Cabanillas ME, "Cabozantinib as salvage therapy for patients with tyrosine kinase inhibitor-refractory differentiated thyroid cancer : results of a multicenter phase II International Thyroid Oncology Group trial", J Clin Oncol, 35(29), pp.3315~3321 (2017)
23. "A study of cabozantinib compared with placebo in subjects with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy"[URL]
24. Sherman SI, "Motesanib diphosphate in progressive differentiated thyroid cancer", N Engl J Med, 359(1), pp.31~42 (2008)
25. Schlumberger MJ, "Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer", J Clin Oncol, 27(23), pp.3794~3801 (2009)
26. Bass MB, "Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer", J Clin Endocrinol Metab, 95(11), pp.5018~5027 (2010)
27. Keefe SM, "Targeting vascular endothelial growth factor receptor in thyroid cancer : the intracellular and extracellular implications", Clin Cancer Res, 16(3), pp.778~783 (2010)
28. Cohen EE, "Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer : results from a phase II study", J Clin Oncol, 26(29), pp.4708~4713 (2008)
29. Locati LD, "Treatment of advanced thyroid cancer with axitinib : Phase 2 study with pharmacokinetic", pharmacodynamic and quality-of-life assessments, 2014, pp.120(17), 2694~2703
30. Cohen EE, "A Phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer : long-term outcomes and pharmacokinetic", pharmacodynamic analyses, 2014, pp.74(6), 1261~1270
31. Bible KC, "Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers : results of a phase 2 consortium study", Lancet Oncol, 11(10), pp.962~972 (2010)
32. Lin YS, "Long-term results of a phase II trial of apatinib for progressive radioiodine refractory differentiated thyroid cancer", J Clin Endocrinol Metab, 106(8), pp.e3027~e3036 (2021)[DOI]
33. Gupta-Abramson V, "Phase II trial of sorafenib in advanced thyroid cancer", J Clin Oncol, 26(29), pp.4714~4719 (2008)
34. Kloos RT, "Phase II trial of sorafenib in metastatic thyroid cancer", J Clin Oncol, 27(10), pp.1675~1684 (2009)
35. Hoftijzer H, "Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma", Eur J Endocrinol, 161(6), pp.923~931 (2009)
36. Cabanillas ME, "Treatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M. D. Anderson experience", J Clin Endocrinol Metab, 95(6), pp.2588~2595 (2010)
37. Ahmed M, "Analysis of the efficacy and toxicity of sorafenib in thyroid cancer : a phase II study in a UK based population", Eur J Endocrinol, 165(2), pp.315~322 (2011)
38. Marotta V, "Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET", Clin Endocrinol(Oxf), 78(5), pp.760~767 (2013)
39. Schneider TC, "Long-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma : final results of a phase II trial", Eur J Endocrinol, 167(5), pp.643~650 (2012)
40. Brose MS, "Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer : a randomised, double-blind, phase 3 trial", Lancet, 384(9940), pp.319~328 (2014)
41. Escudier B, "Sorafenib in advanced clear-cell renal-cell carcinoma", N Engl J Med, 356(2), pp.125~134 (2007)
42. Llovet JM, "Sorafenib in advanced hepatocellular carcinoma", N Engl J Med, 359(4), pp.378~390 (2008)
43. Worden F, "Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer", Endocr Relat Cancer, 22(6), pp.877~887 (2015)
44. Brose MS, "Management of sorafenib-related adverse events : a clinician's perspective", Semin Oncol, 41(Suppl 2), pp.S1~S16 (2014)
45. Shin SY, "Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib", Int J Clin Pharmacol Ther, 51(11), pp.837~846 (2013)
46. Reig M, "Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib", J Hepatol, 61(2), pp.318~324 (2014)
47. Cabanillas ME, "A phase 2 trial of lenvatinib(E7080)in advanced, progressive, radioiodine-refractory, differentiated thyroid cancer : a clinical outcomes and biomarker assessment", Cancer, 121(16), pp.2749~2756 (2015)
48. Schlumberger M, "Lenvatinib versus placebo in radioiodinerefractory thyroid cancer", N Engl J Med, 372(7), pp.621~630 (2015)
49. Schlumberger M, "A phase II trial of the multitargeted tyrosine kinase inhibitor lenvatinib(E7080)in advanced medullary thyroid cancer", Clin Cancer Res, 22(1), pp.44~53 (2016)
50. "A trial of lenvatinib (E7080) in subjects with iodine-131refractory differentiated thyroid cancer to evaluate whether an oral starting dose of 18 milligram (mg) daily will provide comparable efficacy to a 24 mg starting dose, but have a better safety profile"[URL]
51. Hayato S, "Exposure-response analysis and simulation of lenvatinib safety and efficacy in patients with radioiodinerefractory differentiated thyroid cancer", Cancer Chemother Pharmacol, 82(6), pp.971~978 (2018)
52. Kiyota N, "Subgroup analysis of Japanese patients in a phase 3 study of lenvatinib in radioiodine-refractory differentiated thyroid cancer", Cancer Sci, 106(12), pp.1714~1721 (2015)
53. Chen L, "Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma", Thyroid, 21(2), pp.119~124 (2011)
54. Massicotte MH, "Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas : a retrospective study of the TUTHYREF network", Eur J Endocrinol, 170(4), pp.575~582 (2014)
55. Kim M, "Tertiary care experience of sorafenib in the treatment of progressive radioiodine-refractory differentiated thyroid carcinoma : a Korean multicenter study", Thyroid, 28(3), pp.340~348 (2018)
56. Oh HS, "Extended real-world observation of patients treated with sorafenib for radioactive iodine-refractory differentiated thyroid carcinoma and impact of lenvatinib salvage treatment : a Korean multicenter study", Thyroid, 29(12), pp.1804~1810 (2019)
57. Kim MJ, "Tumor doubling time predicts response to sorafenib in radioactive iodine-refractory differentiated thyroid cancer", Endocr J, 66(7), pp.597~604 (2019)
58. Sabra MM, "Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma", Cancer, 123(15), pp.2955~2964 (2017)
59. Tuttle RM, "Novel concepts for initiating multitargeted kinase inhibitors in radioactive iodine refractory differentiated thyroid cancer", Best Pract Res Clin Endocrinol Metab, 31(3), pp.295~305 (2017)
60. Sabra MM, "Prolongation of tumour volume doubling time(midDT)is associated with improvement in disease-specific survival in patients with rapidly progressive radioactive iodine refractory differentiated thyroid cancer selected for molecular targeted therapy", Clin Endocrinol(Oxf), 90(4), pp.617~622 (2019)
61. Cheng L, "Clinicopathological features predict outcomes in patients with radioiodine-refractory differentiated thyroid cancer treated with sorafenib : a real-world study", Oncologist, 25(4), pp.e668~e678 (2020)
62. Lin CY, "Experience of sorafenib treatment in differentiated thyroid cancer from Taiwan", J Formos Med Assoc, 120(1Pt 1), pp.189~195 (2021)
63. Berdelou A, "Lenvatinib for the treatment of radioiodine-refractory thyroid cancer in real-life practice", Thyroid, 28(1), pp.72~78 (2018)
64. Sugino K, "Clinical factors related to the efficacy of tyrosine kinase inhibitor therapy in radioactive iodine refractory recurrent differentiated thyroid cancer patients", Endocr J, 65(3), pp.299~306 (2018)
65. Locati LD, "Real-world efficacy and safety of lenvatinib : data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy", Eur J Cancer, 118, pp.35~40 (2019)
66. Suzuki C, "Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer", Head Neck, 41(9), pp.3023~3032 (2019)
67. Masaki C, "Efficacy and limitations of lenvatinib therapy for radioiodine-refractory differentiated thyroid cancer : real-world experiences", Thyroid, 30(2), pp.214~221 (2020)
68. Aydemirli MD, "Effectiveness and toxicity of lenvatinib in refractory thyroid cancer : Dutch real-life data", Eur J Endocrinol, 182(2), pp.131~138 (2020)
69. Song E, "Lenvatinib for radioactive iodine-refractory differentiated thyroid carcinoma and candidate biomarkers associated with survival : a multicenter study in Korea", Thyroid, 30(5), pp.732~738 (2020)
70. Rendl G, "Real-world data for lenvatinib in radioiodine-refractory differentiated thyroid cancer(RELEVANT) : a retrospective multicentric analysis of clinical practice in Austria", Int J Endocrinol, 2020, pp.8834148~ (2020)
71. Jerkovich F, "Real-life use of lenvatinib in patients with differentiated thyroid cancer : experience from Argentina", Endocrine, 69(1), pp.142~148 (2020)
72. Kish JK, "Lenvatinib and subsequent therapy for radioactive iodine-refractory differentiated thyroid cancer : a real-world study of clinical effectiveness in the United States", Adv Ther, 37(6), pp.2841~2852 (2020)
73. Porcelli T, "Long-term management of lenvatinib-treated thyroid cancer patients : a real-life experience at a single institution", Endocrine, 73(2), pp.358~366 (2021)
74. Platini F, "Late toxicities burden in patients with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib", Endocrine, 73(3), pp.641~647 (2021)
75. Giani C, "Safety and quality-of-life data from an Italian expanded access program of lenvatinib for treatment of thyroid cancer", Thyroid, 31(2), pp.224~232 (2021)
76. Paschke L, "Anti VEGF-TKI treatment and new renal adverse events not reported in phase III trials", Eur Thyroid J, 7(6), pp.308~312 (2018)
77. Iwasaki H, "Renal dysfunction in patients with radioactive iodine-refractory thyroid cancer treated with tyrosine kinase inhibitors: a retrospective study", Medicine(Baltimore), 98(42), pp.e17588~ (2019)
78. Paschke L, "Myocardial infarction after long-term treatment with a tyrosine kinase inhibitor(TKI)with anti-VEGF receptor activity", Case Rep Endocrinol, 2019, pp.7927450~ (2019)
79. Butt MI, "Lenvatinib-induced multiorgan adverse events in Hurthle cell thyroid cancer : a case report", World J Clin Oncol, 12(4), pp.272~281 (2021)
80. Tamai T, "Dose finding of lenvatinib in subjects with advanced hepatocellular carcinoma based on population pharmacokinetic and exposure-response analyses", J Clin Pharmacol, 57(9), pp.1138~1147 (2017)
81. Subbiah V, "Precision targeted therapy with BLU-667 for RET-driven cancers", Cancer Discov, 8(7), pp.836~849 (2018)
82. Markham A, "Pralsetinib : first approval", Drugs, 80(17), pp.1865~1870 (2020)
83. Wirth LJ, "Efficacy of selpercatinib in RET-altered thyroid cancers", N Engl J Med, 383(9), pp.825~835 (2020)
84. Markham A, "Selpercatinib : first approval", Drugs, 80(11), pp.1119~1124 (2020)
85. Laetsch TW, "Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions : phase 1 results from a multicentre, open-label, phase 1", 2 study, 2018, pp.19(5), 705~714
86. Kelly LM, "Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer", Proc Natl Acad Sci U S A, 111(11), pp.4233~4238 (2014)
87. de Salins V, "Complete response in anaplastic lymphoma kinase-rearranged oncocytic thyroid cancer : a case report and review of literature", World J Clin Oncol, 11(7), pp.495~503 (2020)